Similar data revealed associations of tumor responsiveness between high CA9 expression and anti-VEGF therapy agents such as sunitinib, sorafenib, bevacizumab, temsirolimus and vatalanib [14], [47]. This evidence concerns the gene CA9 and neoplasm.